Cargando…
Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors
PURPOSE: Immune checkpoint inhibitors (ICIs) have been approved for various types of cancer; however, they cause a broad spectrum of immune-related adverse events (irAEs). The association between the development of irAEs and the clinical benefit remains uncertain. We aimed to evaluate the associatio...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305832/ https://www.ncbi.nlm.nih.gov/pubmed/32606951 http://dx.doi.org/10.2147/CMAR.S247554 |
_version_ | 1783548544035061760 |
---|---|
author | Shimozaki, Keitaro Sukawa, Yasutaka Beppu, Noriko Kurihara, Isao Suzuki, Shigeaki Mizuno, Ryuichi Funakoshi, Takeru Ikemura, Shinnosuke Tsugaru, Kai Togasaki, Kazuhiro Kawasaki, Kenta Hirata, Kenro Hayashi, Hideyuki Hamamoto, Yasuo Takaishi, Hiromasa Kanai, Takanori |
author_facet | Shimozaki, Keitaro Sukawa, Yasutaka Beppu, Noriko Kurihara, Isao Suzuki, Shigeaki Mizuno, Ryuichi Funakoshi, Takeru Ikemura, Shinnosuke Tsugaru, Kai Togasaki, Kazuhiro Kawasaki, Kenta Hirata, Kenro Hayashi, Hideyuki Hamamoto, Yasuo Takaishi, Hiromasa Kanai, Takanori |
author_sort | Shimozaki, Keitaro |
collection | PubMed |
description | PURPOSE: Immune checkpoint inhibitors (ICIs) have been approved for various types of cancer; however, they cause a broad spectrum of immune-related adverse events (irAEs). The association between the development of irAEs and the clinical benefit remains uncertain. We aimed to evaluate the association of irAEs and the treatment efficacy in real-world practice. PATIENTS AND METHODS: We conducted a retrospective study on patients with recurrent or metastatic non-small-cell lung cancer, malignant melanoma, renal cell carcinoma, or gastric cancer who received anti-PD-1/PD-L1 antibodies (nivolumab, pembrolizumab, or atezolizumab) at the Keio University Hospital between September 2014 and January 2019. We recorded treatment-related AEs from medical records and graded them using the Common Terminology Criteria for Adverse Events version 4. We performed an overall survival (OS) analysis using a Cox proportional hazards model and the shared frailty model. RESULTS: Of 212 patients eligible for this study, 108 experienced irAEs and 42 developed multiple irAEs. The median OS was significantly longer in the irAEs than in the no-irAE group (28.1 months vs 12.7 months; hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.33–0.73; P = 0.0004). Moreover, the OS of patients with multiple irAEs was significantly longer than that of patients with a single irAE (42.3 months vs 18.8 months; HR, 0.473; 95% CI, 0.346–0.647; P < 0.0001). CONCLUSION: Our single-center retrospective study revealed a significant tendency associating the development of multiple irAEs with favorable prognoses. |
format | Online Article Text |
id | pubmed-7305832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-73058322020-06-29 Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors Shimozaki, Keitaro Sukawa, Yasutaka Beppu, Noriko Kurihara, Isao Suzuki, Shigeaki Mizuno, Ryuichi Funakoshi, Takeru Ikemura, Shinnosuke Tsugaru, Kai Togasaki, Kazuhiro Kawasaki, Kenta Hirata, Kenro Hayashi, Hideyuki Hamamoto, Yasuo Takaishi, Hiromasa Kanai, Takanori Cancer Manag Res Original Research PURPOSE: Immune checkpoint inhibitors (ICIs) have been approved for various types of cancer; however, they cause a broad spectrum of immune-related adverse events (irAEs). The association between the development of irAEs and the clinical benefit remains uncertain. We aimed to evaluate the association of irAEs and the treatment efficacy in real-world practice. PATIENTS AND METHODS: We conducted a retrospective study on patients with recurrent or metastatic non-small-cell lung cancer, malignant melanoma, renal cell carcinoma, or gastric cancer who received anti-PD-1/PD-L1 antibodies (nivolumab, pembrolizumab, or atezolizumab) at the Keio University Hospital between September 2014 and January 2019. We recorded treatment-related AEs from medical records and graded them using the Common Terminology Criteria for Adverse Events version 4. We performed an overall survival (OS) analysis using a Cox proportional hazards model and the shared frailty model. RESULTS: Of 212 patients eligible for this study, 108 experienced irAEs and 42 developed multiple irAEs. The median OS was significantly longer in the irAEs than in the no-irAE group (28.1 months vs 12.7 months; hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.33–0.73; P = 0.0004). Moreover, the OS of patients with multiple irAEs was significantly longer than that of patients with a single irAE (42.3 months vs 18.8 months; HR, 0.473; 95% CI, 0.346–0.647; P < 0.0001). CONCLUSION: Our single-center retrospective study revealed a significant tendency associating the development of multiple irAEs with favorable prognoses. Dove 2020-06-16 /pmc/articles/PMC7305832/ /pubmed/32606951 http://dx.doi.org/10.2147/CMAR.S247554 Text en © 2020 Shimozaki et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Shimozaki, Keitaro Sukawa, Yasutaka Beppu, Noriko Kurihara, Isao Suzuki, Shigeaki Mizuno, Ryuichi Funakoshi, Takeru Ikemura, Shinnosuke Tsugaru, Kai Togasaki, Kazuhiro Kawasaki, Kenta Hirata, Kenro Hayashi, Hideyuki Hamamoto, Yasuo Takaishi, Hiromasa Kanai, Takanori Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors |
title | Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors |
title_full | Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors |
title_fullStr | Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors |
title_full_unstemmed | Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors |
title_short | Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors |
title_sort | multiple immune-related adverse events and anti-tumor efficacy: real-world data on various solid tumors |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305832/ https://www.ncbi.nlm.nih.gov/pubmed/32606951 http://dx.doi.org/10.2147/CMAR.S247554 |
work_keys_str_mv | AT shimozakikeitaro multipleimmunerelatedadverseeventsandantitumorefficacyrealworlddataonvarioussolidtumors AT sukawayasutaka multipleimmunerelatedadverseeventsandantitumorefficacyrealworlddataonvarioussolidtumors AT beppunoriko multipleimmunerelatedadverseeventsandantitumorefficacyrealworlddataonvarioussolidtumors AT kuriharaisao multipleimmunerelatedadverseeventsandantitumorefficacyrealworlddataonvarioussolidtumors AT suzukishigeaki multipleimmunerelatedadverseeventsandantitumorefficacyrealworlddataonvarioussolidtumors AT mizunoryuichi multipleimmunerelatedadverseeventsandantitumorefficacyrealworlddataonvarioussolidtumors AT funakoshitakeru multipleimmunerelatedadverseeventsandantitumorefficacyrealworlddataonvarioussolidtumors AT ikemurashinnosuke multipleimmunerelatedadverseeventsandantitumorefficacyrealworlddataonvarioussolidtumors AT tsugarukai multipleimmunerelatedadverseeventsandantitumorefficacyrealworlddataonvarioussolidtumors AT togasakikazuhiro multipleimmunerelatedadverseeventsandantitumorefficacyrealworlddataonvarioussolidtumors AT kawasakikenta multipleimmunerelatedadverseeventsandantitumorefficacyrealworlddataonvarioussolidtumors AT hiratakenro multipleimmunerelatedadverseeventsandantitumorefficacyrealworlddataonvarioussolidtumors AT hayashihideyuki multipleimmunerelatedadverseeventsandantitumorefficacyrealworlddataonvarioussolidtumors AT hamamotoyasuo multipleimmunerelatedadverseeventsandantitumorefficacyrealworlddataonvarioussolidtumors AT takaishihiromasa multipleimmunerelatedadverseeventsandantitumorefficacyrealworlddataonvarioussolidtumors AT kanaitakanori multipleimmunerelatedadverseeventsandantitumorefficacyrealworlddataonvarioussolidtumors |